1. Home
  2. MLYS vs NPKI Comparison

MLYS vs NPKI Comparison

Compare MLYS & NPKI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLYS
  • NPKI
  • Stock Information
  • Founded
  • MLYS 2019
  • NPKI 1932
  • Country
  • MLYS United States
  • NPKI United States
  • Employees
  • MLYS N/A
  • NPKI N/A
  • Industry
  • MLYS Biotechnology: Pharmaceutical Preparations
  • NPKI Metal Fabrications
  • Sector
  • MLYS Health Care
  • NPKI Industrials
  • Exchange
  • MLYS Nasdaq
  • NPKI Nasdaq
  • Market Cap
  • MLYS 1.0B
  • NPKI 722.7M
  • IPO Year
  • MLYS 2023
  • NPKI N/A
  • Fundamental
  • Price
  • MLYS $13.84
  • NPKI $8.57
  • Analyst Decision
  • MLYS Strong Buy
  • NPKI Strong Buy
  • Analyst Count
  • MLYS 4
  • NPKI 1
  • Target Price
  • MLYS $27.00
  • NPKI $12.00
  • AVG Volume (30 Days)
  • MLYS 827.2K
  • NPKI 924.8K
  • Earning Date
  • MLYS 08-12-2025
  • NPKI 08-04-2025
  • Dividend Yield
  • MLYS N/A
  • NPKI N/A
  • EPS Growth
  • MLYS N/A
  • NPKI N/A
  • EPS
  • MLYS N/A
  • NPKI N/A
  • Revenue
  • MLYS N/A
  • NPKI $233,299,000.00
  • Revenue This Year
  • MLYS N/A
  • NPKI $15.28
  • Revenue Next Year
  • MLYS N/A
  • NPKI $9.62
  • P/E Ratio
  • MLYS N/A
  • NPKI N/A
  • Revenue Growth
  • MLYS N/A
  • NPKI 312.30
  • 52 Week Low
  • MLYS $8.24
  • NPKI $4.76
  • 52 Week High
  • MLYS $18.38
  • NPKI $8.88
  • Technical
  • Relative Strength Index (RSI)
  • MLYS 42.26
  • NPKI N/A
  • Support Level
  • MLYS $12.95
  • NPKI N/A
  • Resistance Level
  • MLYS $14.09
  • NPKI N/A
  • Average True Range (ATR)
  • MLYS 0.77
  • NPKI 0.00
  • MACD
  • MLYS -0.14
  • NPKI 0.00
  • Stochastic Oscillator
  • MLYS 28.24
  • NPKI 0.00

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

About NPKI NPK International Inc. Common Stock

NPK International Inc is a temporary worksite access solutions company that manufactures, sells, and rents recyclable composite matting products, along with a full suite of services, including planning, logistics, and site restoration. The company generates majority of revenue from the rental of recyclable composite matting systems, along with related site construction and services to customers in various markets including power transmission, oil and natural gas exploration and production, pipeline, renewable energy, petrochemical, construction and other industries within the United States and United Kingdom.

Share on Social Networks: